Official ESCRS | European Society of Cataract & Refractive Surgeons


OMNI™ open-angle glaucoma treatment: an 18-month follow-up

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma II

Venue: Poster Village: Pod 3

First Author: : I.Grabska-Liberek POLAND

Co Author(s): :    P. Duda   M. Rogowska   J. Majszyk-Ionescu   A. Skowyra   I. Kane           

Abstract Details


To analyze the safety and efficacy of the OMNI TM procedure in reducing intraocular pressure (IOP) and number of glaucoma drugs in eyes with open-angle glaucoma (OAG).


OMNI TM is a new surgical procedure for OAG treatment and the first non-implantable minimally-invasive glaucoma surgery. It uses a single, self-sealing clear corneal incision with a 360-degree viscodilation of Schlemm’s canal, followed by a transluminal trabeculotomy, performed via gonioscopic guidance.


A single-surgeon prospective clinical study. 24 eyes of 19 OAG adult patients underwent OMNI TM surgery. 14 eyes underwent OMNI TM alone, and 10 eyes underwent OMNI TM combined with cataract surgery. Changes in intraocular pressure (IOP) and postoperative complications will be examined. Success is defined as post-operative IOP reduction ≥ 20% without glaucoma medication ("complete success"), or with topical treatment ("qualified success"). The number of medications before and after surgery will be considered.


19patients underwent the OMNI TM procedure. Preoperative mean IOP was 21,42 ±6,06 mmHg. Postoperative IOP decreased to a mean of 13,75±4,45, 15,13±4,05, 13,79±3,03, 13,58±2,97 and 13,86±3,94 mmHg at 1 week, 1 month, 3 months, 6 months and 1 year.  Given those same time increments, the number of anti-glaucoma medications dropped from a mean of 2,92 preoperatively to 0,08, 0,17, 0,58, 1,16 and 1,50. Complications were limited to IOP-spikes (nine eyes), hyphema (six eyes) and fibrin in the anterior chamber (five cases) that resolved the first week post-op. 18-month data will be presented during the meeting.


The OMNI TM is a promising approach for the treatment of non-advanced OAG. The procedure achieves reduction of IOP and number of glaucoma medications. It also demonstrates a good safety profile. The main advantages of the procedure are: short surgical learning curve, time-efficient, implant-free and sutureless, can be combined with cataract surgery, sparing of the conjunctiva and sclera of incisions. Further studies needed.

Financial Disclosure:

... is employed by a for-profit company with an interest in the subject of the presentation

Back to previous